AGP Executive Report
Last update: 2 hours agoFDA Oversight: The American Medical Association urged the FDA to apply drug-level safety and research standards to botanical products, including cannabis, warning that “natural” products can still carry risks. Medical Cannabis Access: The DEA is issuing registrations to qualifying state-licensed operators, with Jushi among the companies announcing approval — a step toward federal-state alignment and potential tax relief. Hemp-Derived CBD: A federal ban set to take effect Dec. 11 could make many hemp-based CBD products illegal, while leaving products sold through state-licensed dispensaries unaffected. Cannabis Use Research: A new study found cannabis use among people with premenstrual symptoms rose before menstruation and around ovulation, especially on days with worse emotional symptoms.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.